Approval：即将到来的日期

最近

• 健康2026/10/04@HealthDesk

  FDA Approves AbbVie's Juvmo, First D1/D5 Agonist for Parkinson's

  1 North Waukegan Road, North Chicago, Illinois, United StatesAbbVie

  

  开始于 2026/09/25已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 83%总体可信度: 83%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 5 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉10天前Pharmaceutical Technology^[3] (28 Sept 2026) says that per the FDA's website tavapadon was approved on 25 September, and TIKR^[5] cites Reuters for approval 'on Friday, September 25'; AbbVie's^[1] own release is dated 28 September.

  On 25 September 2026 the FDA approved AbbVie's Juvmo (tavapadon), a once-daily tablet and the first selective D1/D5 receptor agonist approved for adults with Parkinson's disease; AbbVie announced it on 28 September.

  00
• 健康2026/10/04@HealthDesk

  EU Approves Sanofi's Cenrifki, a First Disability-Targeting SPMS Drug

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  开始于 2026/06/23已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 86%总体可信度: 86%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉104天前Sanofi's^[1] press release is datelined "Paris, June 23, 2026" and PharmaTimes^[4]' report of the approval is dated 23 June 2026.

  On 23 June 2026 the European Commission approved Sanofi's Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis without relapses, the first EU medicine aimed at disability progression in that group.

  00
• 健康2026/10/04@HealthDesk

  FDA Approves Wegovy HD 7.2 mg, Delivering 20.7% Mean Weight Loss

  Novo Allé 1, Bagsværd, DenmarkNovo Nordisk

  

  开始于 2026/03/19已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 84%总体可信度: 84%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉200天前Novo's announcement is dated "Bagsværd, Denmark, 19 March 2026"; the Boston Globe^[2] published it 2026-03-19T18:24Z and Healio^[3] is dated 2026-03-19.

  On 19 March 2026 the US FDA approved Wegovy HD (semaglutide 7.2 mg, once weekly) for weight loss after the STEP UP trial showed 20.7% mean weight loss, the first GLP-1 approval under the FDA's priority voucher pilot.

  00
• 健康2026/10/04@HealthDesk

  FDA Approves Novo Nordisk's Wegovy Pill, the First Oral GLP-1 for Weight Loss

  Novo Allé 1, Bagsværd, DenmarkNovo Nordisk

  

  开始于 2025/12/22已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 86%总体可信度: 86%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉287天前Novo's announcement is dated "Bagsværd, Denmark, 22 December 2025"; its full-year report states "On 22 December, the US FDA approved" the pill; Fox 32 published 2025-12-22 and PharmExec^[3] 2025-12-23.

  On 22 December 2025 the US FDA approved the once-daily Wegovy pill (oral semaglutide 25 mg), the first oral GLP-1 for weight management, which showed 16.6% mean weight loss in the OASIS 4 trial.

  00
• 健康2026/10/04@HealthDesk

  FDA Approves GSK's Exdensur, a Twice-Yearly Severe Asthma Biologic

  GSK House, 980 Great West Road, Brentford, United KingdomGSK

  

  开始于 2025/12/16已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 80%总体可信度: 80%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉293天前The Business Wire^[4] copy of GSK's^[1] release carries the 16 December 2025 stamp in its URL (20251216) and The Pharma Letter^[3], dated 18 December, says GSK 'yesterday announced' the approval.

  On 16 December 2025 the US FDA approved Exdensur (depemokimab-ulaa) as add-on maintenance treatment for severe eosinophilic asthma in people aged 12 and over, dosed twice a year.

  00
• 健康2026/10/04@HealthDesk

  FDA Approves GSK's Blenrep for Relapsed Multiple Myeloma

  GSK House, 980 Great West Road, Brentford, United KingdomGSK

  

  开始于 2025/10/23已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 78%总体可信度: 78%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉347天前GSK's^[1] press release states the FDA approval; the 23 October 2025 date is given by Pharmaceutical Executive's 24 October article and by a search summary of GSK's announcement, and the PharmaLetter^[3] calls it a re-approval.

  On 23 October 2025 the US FDA approved Blenrep with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior lines of therapy.

  00
• 健康2026/10/04@HealthDesk

  FDA Approves Pfizer-BioNTech's Comirnaty, the First COVID-19 Vaccine

  66 Hudson Boulevard East, New York, New York, United StatesPfizer

  

  开始于 2021/08/23已确认日期确定性: 已确认已公布为确定日期来源对日期的表述有多确定：已确认、已排期、预估、已推迟或未核实。显示所有“已确认”的图钉可信度 90%总体可信度: 90%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半显示所有可信度不低于 75% 的图钉5.1年前FDA's^[1] announcement, BioSpace^[3] (23 August 2021), RAPS^[4] (23 August 2021) and BioPharm International^[2] ('On August 23, 2021') all give the same day.

  On 23 August 2021 the FDA approved Comirnaty, the Pfizer-BioNTech COVID-19 vaccine, for people 16 and older, making it the first approved COVID-19 vaccine and the first approved mRNA therapy in the US.

  00